Long-term follow-up of the Adjuvant Tamoxifen Longer Against Shorter (ATLAS[NCT00003016]) trial demonstrated that 10 years of tamoxifen therapy was superior to 5 years of tamoxifen therapy.
Between 1996 and 2005, 12,894 women with early breast cancer were randomly assigned to receive 10 years or 5 years of tamoxifen therapy.
The following results were reported:[43][Level of evidence A1]Study results revealed that 10 years of tamoxifen reduced the risk of breast cancer recurrence (617 recurrences for 10 years of tamoxifen vs.
711 recurrences for 5 years of tamoxifen;P= .002), reduced breast cancer mortality (331 deaths for 10 years of tamoxifen vs.